What is it about?
1. Cancer Immunology Research (Panda et al. 2025, Dec) "Antibody-Mediated Inhibition of HLA/LILR Interactions Breaks Innate Immune Tolerance and Induces Antitumor Immunity" PMID: 41032026 | DOI: 10.1158/2326-6066.CIR-25-0343 2. Communications Biology (Jiang et al. 2026, Feb) "Structural mechanism of anti-MHC-I antibody blocking of inhibitory NK cell receptors in tumor immunity" PMID: 41629525 | DOI: 10.1038/s42003-026-09641-8 These two complementary studies explore a new way to help the immune system recognize and attack cancer by activating its innate defenses. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) discovered that cancer cells use common immune molecules—called HLA class I—to send “stop” signals to natural killer (NK) cells and other innate immune cells. These signals prevent the immune system from doing its job. The research teams tested antibodies that block these inhibitory signals. By targeting conserved regions of HLA class I, the antibodies prevent HLA from interacting with inhibitory receptors on NK and myeloid cells. In laboratory experiments and humanized mouse models, this approach reactivated suppressed NK cells and significantly reduced tumor growth. One of the studies also identified a structural mechanism explaining how an anti–MHC-I antibody physically blocks inhibitory receptor binding, leading to immune activation. Together, the two papers reveal that HLA class I molecules act as a previously unrecognized “immune brake” on the innate immune system in cancer.
Featured Image
Why is it important?
Most current cancer immunotherapies focus on T cells and adaptive immunity, yet many tumors either fail to respond or eventually become resistant to these treatments. These studies highlight an alternative strategy: unleashing innate immune cells, particularly NK cells, which can recognize and kill cancer cells without prior sensitization. Importantly, the findings show that HLA class I—long thought to protect tumors primarily by avoiding T cell detection—also broadly suppresses innate immune responses. By targeting HLA-mediated inhibitory signaling, a single antibody can release multiple suppressive pathways at once. This positions HLA class I as a central checkpoint controlling innate immune tolerance in tumors. This work expands the concept of immune checkpoint inhibition beyond T cells and opens the door to new therapies for patients whose cancers do not respond to existing immunotherapies.
Perspectives
Targeting HLA-mediated innate immune inhibition represents a promising new direction in cancer treatment. Because the antibodies bind conserved regions of HLA class I, this strategy may be broadly applicable across tumor types and patient populations. It could also be combined with existing T cell–based immunotherapies to produce more durable and effective responses. Future studies will focus on optimizing antibody design, evaluating safety, and testing this approach in additional cancer models. If successfully translated to the clinic, this strategy could provide new options for treating advanced, metastatic, or immunotherapy-resistant cancers by mobilizing the body’s innate immune defenses.
Dr. Jiansheng Jiang
National Institute of Allergy and Infectious Diseases, USA
Read the Original
This page is a summary of: Structural mechanism of anti-MHC-I antibody blocking of inhibitory NK cell receptors in tumor immunity, Communications Biology, February 2026, Springer Science + Business Media,
DOI: 10.1038/s42003-026-09641-8.
You can read the full text:
Contributors
The following have contributed to this page
